This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Pharmacokinetics of Voriconazole in Obese Subjects

This study has been completed.
Sponsor:
Collaborators:
TKL Research, Inc.
Pfizer
Information provided by (Responsible Party):
Manjunath Prakash Pai, University of Michigan
ClinicalTrials.gov Identifier:
NCT01030653
First received: December 10, 2009
Last updated: December 16, 2016
Last verified: December 2016
  Purpose
Obese subjects may require a higher fixed oral maintenance dosing regimen of voriconazole compared to normal weight subjects to achieve comparable plasma exposures. The current study is designed to address this issue.

Condition Intervention Phase
Healthy Drug: Voriconazole low dose Drug: Voriconazole high dose Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Official Title: Pharmacokinetics of Voriconazole in Obese Subjects

Resource links provided by NLM:


Further study details as provided by Manjunath Prakash Pai, University of Michigan:

Primary Outcome Measures:
  • Steady-State Cmax and Cmin of Two Voriconazole Dosing Regimens [ Time Frame: Day 5 ]

    Cmax is the maximum concentration, and Cmin is the minimum concentration. These measurements are based on analysis of plasma. The units shown are milligrams of voriconazole per liter of plasma. The two dosing regimens are:

    1. a loading dose (400 mg x 2 doses, day 1) and maintenance doses (200 mg every 12 hours x 7 doses) in obese subjects.
    2. a loading dose (400 mg x 2 doses, day 1) and maintenance doses (300 mg every 12 hours x 7 doses) in obese subjects.

  • Geometric Mean Ratio of the AUC Between the High and Low Dose Voriconazole [ Time Frame: 14 days ]
    AUC is the area under the concentration-time curve. The Geometric Mean Ratio and 90% confidence interval around this value permit an assessment of the bioequivalence of two dosing regimens in the same group. The geometric mean is computed based on the ratio of the AUC value from the high dose compared to the AUC value from the low dose for each individual. This ratio provides a more robust interpretation of the differences between the two dosing arms because each individual serves as their own control.


Secondary Outcome Measures:
  • The Area Under the Curve Over the Dosing Interval for All Participants While on the High Dose and Low Dose Interventions. [ Time Frame: 12 hours ]

Enrollment: 10
Study Start Date: November 2009
Study Completion Date: May 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Voriconazole low dose first then high dose
Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (200 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (300 mg Every 12 Hours x 7 Doses)
Drug: Voriconazole low dose
Voriconazole 400 mg po x 2 doses (loading dose)then 200 mg po twice daily x 7 doses
Other Name: Vfend
Drug: Voriconazole high dose
Voriconazole 400 mg po x 2 doses (loading dose)then 300 mg po twice daily x 7 doses
Other Name: Vfend
Experimental: Voriconazole high dose first then low dose
Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (300 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (200 mg Every 12 Hours x 7 Doses)
Drug: Voriconazole low dose
Voriconazole 400 mg po x 2 doses (loading dose)then 200 mg po twice daily x 7 doses
Other Name: Vfend
Drug: Voriconazole high dose
Voriconazole 400 mg po x 2 doses (loading dose)then 300 mg po twice daily x 7 doses
Other Name: Vfend

Detailed Description:

The prevalence of obesity has increased tremendously in the past two decades. An estimated 1 out of 5 persons in the United States are classified as obese. Under representation of obese patients in pharmacokinetic trials grossly limit generalizability of drug dosing recommendations in this emerging population. No published pharmacokinetic studies of voriconazole dosing in patients with obesity currently exist in the literature. Specifically,voriconazole pharmacokinetic data from subjects with a body mass index (BMI) ≥ 35 kg/m2(Class II and III obesity) are limited.

Voriconazole is available as both an intravenous and oral formulation. Anecdotal experience suggest that the use of oral voriconazole to be significantly more prevalent that that of intravenous therapy. The current oral recommended dosing regimen for voriconazole includes use of 200 mg every 12 hours for patients who are over 40 kg. The dosage can be increased to 300 mg by mouth every 12 hours in situations where a sufficient clinical response is not noted. A weight based dosing strategy is also utilized in patients with more serious infections (3-6 mg/kg IV Q 12 hours) such as invasive aspergillosis. Voriconazole demonstrates non-linear pharmacokinetics and so dosing based on total body weight may result in non-dose proportional exposure. For example, a 1.5 fold dose increment in voriconazole from 200 mg to 300 mg every 12 hours results in a 2.5 fold increase in exposure. The most appropriate body size descriptor is unknown (i.e. ideal body weight, fat free weight, lean body weight, etc.) for most antimicrobials, including voriconazole. As a consequence, the appropriateness of weight-based voriconazole dosage selection in obese patients is not known. Intuitively, weight based dosing (on total body weight) in this population could lead to higher than expected exposures (non-linear pharmacokinetics) and lead to potential adverse events. Therapeutic drug monitoring is increasingly advocated as a system to improve voriconazole dosing. However, an assay to measure voriconazole concentrations in the clinic is not routinely available. Hence, the current pilot study proposes to characterize the pharmacokinetic profile of voriconazole in obese subjects using two fixed dose regimens.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. males and females, 18 to 50 years of age;
  2. non-smoking or light-smoking (≤5 cigarettes per day) volunteers;
  3. BMI ≥ 35 kg/m2;
  4. female subjects of childbearing potential either surgically sterilized, using an effective method of contraception (diaphragm, cervical cap, condom) or agree to abstain from sex from time of prestudy screening, during entire study period and 1 week following the study period.

Exclusion Criteria:

  1. History of significant hypersensitivity reaction or intolerance to voriconazole, fluconazole,itraconazole, posaconazole, or ketoconazole ;
  2. history of significant clinical illness requiring pharmacological management;
  3. abnormal serum electrolyte or complete blood count requiring further clinical work-up;
  4. transaminases (AST or ALT) >2.5 x upper limit of normal;
  5. estimated creatinine clearance <50 mL/min (Cockcroft-Gault equation);
  6. positive urine pregnancy test (if female);
  7. abnormal electrocardiogram (ECG) as judged by study physician;
  8. unable to tolerate venipuncture and multiple blood draws;
  9. clinically significant abnormal physical examination defined as a physical finding requiring further clinical work-up.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01030653

Locations
United States, New Jersey
TKL Research Inc
Paramus, New Jersey, United States, 07652
Sponsors and Collaborators
Manjunath Prakash Pai
TKL Research, Inc.
Pfizer
Investigators
Principal Investigator: Manjunath P Pai, PharmD University of Michigan
  More Information

Publications:
Responsible Party: Manjunath Prakash Pai, Associate Professor, University of Michigan
ClinicalTrials.gov Identifier: NCT01030653     History of Changes
Other Study ID Numbers: 09010
Study First Received: December 10, 2009
Results First Received: June 23, 2011
Last Updated: December 16, 2016

Keywords provided by Manjunath Prakash Pai, University of Michigan:
Voriconazole
Pharmacokinetics
Obese
Healthy Volunteer

Additional relevant MeSH terms:
Voriconazole
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors

ClinicalTrials.gov processed this record on August 16, 2017